Indoxyl Sulfate Contributes to Impaired Height Velocity in (Pre)School Children
- PMID: 38899199
- PMCID: PMC11184389
- DOI: 10.1016/j.ekir.2024.03.021
Indoxyl Sulfate Contributes to Impaired Height Velocity in (Pre)School Children
Abstract
Introduction: Growth failure is considered the most important clinical outcome parameter in childhood chronic kidney disease (CKD). Central to the pathophysiology of growth failure is the presence of a chronic proinflammatory state, presumed to be partly driven by the accumulation of uremic toxins. In this study, we assessed the association between uremic toxin concentrations and height velocity in a longitudinal multicentric prospective pediatric CKD cohort of (pre)school-aged children and children during pubertal stages.
Methods: In a prospective, multicentric observational study, a selection of uremic toxin levels of children (aged 0-18 years) with CKD stage 1 to 5D was assessed every 3 months (maximum 2 years) along with clinical growth parameters. Linear mixed models with a random slope for age and a random intercept for child were fitted for height (in cm and SD scores [SDS]). A piecewise linear association between age and height was assumed.
Results: Data analysis included data from 560 visits of 81 children (median age 9.4 years; 2/3 male). In (pre)school aged children (aged 2-12 years), a 10% increase in concurrent indoxyl sulfate (IxS, total) concentration resulted in an estimated mean height velocity decrease of 0.002 SDS/yr (P < 0.05), given that CKD stage, growth hormone (GH), bicarbonate concentration, and dietary protein intake were held constant. No significant association with height velocity was found in children during pubertal stages (aged >12 years).
Conclusion: The present study demonstrated that, especially IxS contributes to a lower height velocity in (pre)school children, whereas we could not find a role for uremic toxins with height velocity during pubertal stages.
Keywords: child; chronic kidney disease; dialysis; growth failure; inflammation; uremic toxins.
© 2024 International Society of Nephrology. Published by Elsevier Inc.
Similar articles
-
Protein-bound uremic toxin lowering strategies in chronic kidney disease: a systematic review and meta-analysis.J Nephrol. 2021 Dec;34(6):1805-1817. doi: 10.1007/s40620-020-00955-2. Epub 2021 Jan 23. J Nephrol. 2021. PMID: 33484425
-
Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease.BMC Nephrol. 2017 Jan 25;18(1):35. doi: 10.1186/s12882-017-0457-1. BMC Nephrol. 2017. PMID: 28122514 Free PMC article.
-
Dietary fibre intake is low in paediatric chronic kidney disease patients but its impact on levels of gut-derived uraemic toxins remains uncertain.Pediatr Nephrol. 2021 Jun;36(6):1589-1595. doi: 10.1007/s00467-020-04840-9. Epub 2021 Jan 2. Pediatr Nephrol. 2021. PMID: 33387017
-
Increased response, but lower responsiveness, to growth hormone (GH) in very young children (aged 0-3 years) with idiopathic GH Deficiency: analysis of data from KIGS.J Clin Endocrinol Metab. 2005 Apr;90(4):1966-71. doi: 10.1210/jc.2004-1051. Epub 2005 Jan 5. J Clin Endocrinol Metab. 2005. PMID: 15634724
-
Cardiotoxicity of Uremic Toxins: A Driver of Cardiorenal Syndrome.Toxins (Basel). 2018 Sep 1;10(9):352. doi: 10.3390/toxins10090352. Toxins (Basel). 2018. PMID: 30200452 Free PMC article. Review.
Cited by
-
Gut-derived metabolites as treatment targets in chronic kidney disease-an avenue toward personalized medicine.Pediatr Nephrol. 2025 May;40(5):1505-1510. doi: 10.1007/s00467-024-06609-w. Epub 2025 Jan 16. Pediatr Nephrol. 2025. PMID: 39820506 Free PMC article. No abstract available.
-
Cinacalcet: Addressing the Unmet Clinical Need in the Management of CKD-Mineral and Bone Disorder in Infants on Dialysis.Kidney Int Rep. 2024 Jun 10;9(8):2332-2334. doi: 10.1016/j.ekir.2024.06.014. eCollection 2024 Aug. Kidney Int Rep. 2024. PMID: 39156150 Free PMC article. No abstract available.
-
Gut microbiota-targeted therapies in pediatric chronic kidney disease: gaps and opportunities.Pediatr Nephrol. 2025 May 1. doi: 10.1007/s00467-025-06789-z. Online ahead of print. Pediatr Nephrol. 2025. PMID: 40307477 Review.
-
Assessment of Within- and Inter-Patient Variability of Uremic Toxin Concentrations in Children with CKD.Toxins (Basel). 2024 Aug 9;16(8):349. doi: 10.3390/toxins16080349. Toxins (Basel). 2024. PMID: 39195759 Free PMC article.
References
LinkOut - more resources
Full Text Sources